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Abstract
Background and objectives: Hydroxyethyl starch (HES) 130/0.4 is considered an effective plasma 
expander when compared to crystalloids. There is controversy around its superiority regarding 
hemodynamic optimization and about possible detrimental effects on coagulation. The aim of this 
study was to compare the effects of HES 130/0.4 to lactated Ringer solution during hip arthroplasty 
in adult patients under spinal anesthesia regarding intraoperative bleeding, hemodynamic 
parameters, coagulation proﬁ le, transfusion requirements and clinical outcomes.
Methods: In this randomized, controlled trial, 48 patients scheduled for hip arthroplasty with spinal 
anesthesia were randomized into two groups: 24 patients were allocated to receive a preload 
of 15 mL.kg-1 of HES 130/0.4 and 24 patients received a preload of 30 mL.kg-1 lactated Ringer 
solution before surgery. Hemodynamic measurements, hemoglobin concentrations, biochemical 
parameters and coagulation tests were evaluated in three periods during surgical procedure. 
Patients received medical follow-up during their hospital stay and up to postoperative 30 days. 
Primary outcome was the requirement of red blood cell transfusion between groups during hospital 
stay. Secondary outcome were hemodynamic parameters, length of hospital stay, mortality and 
occurrence of clinical postoperative complications.
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Results: Red blood cell transfusion was required in 17% of patients in the HES group and in 46% in 
the Ringer group (p = .029). Postoperative infections were more frequently observed in the Ringer 
group (17%) compared to the HES group (0), p = .037. There were no signiﬁ cant differences between 
groups in mortality, hospital length of stay and clinical complications other than infection. 
Conclusions: During hip arthroplasty, patients treated with hypervolemic hemodilution with 
hydroxyethyl starch 130/0.4 required less transfusion and presented lower infection rate  compared 
to patients who received lactated Ringer.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.   
Introduction
The best type of ﬂ uid for intravascular volume replacement in 
major surgeries remains a matter of controversy 1. Synthetic 
colloids seem to be more attractive because of their ability 
to maintain intravascular ﬂ uid volume and regional tissue per-
fusion more efﬁ ciently than crystalloids 2-4. However, colloid so-
lutions such as hydroxyethyl starchs (HES), gelatin and dextran, 
when compared to crystalloid solutions are more expensive and 
may be associated with adverse effects, such as acute renal 
failure, and platelet and coagulation disorders 5,6. 
Third-generation HES - as HES 130/0.4 and HES 130/0.42 
- relate to less adverse effects ratio, probably due to struc-
tural moieties, as they present lower molecular weight and 
the degree of molar substitution, compared to other HES 
solutions 7,8.
A multicenter randomized trial showed that allogenic 
transfusion increases morbidity and mortality rates in 
critically ill patients11. Adverse risks associated with blood 
transfusion include higher infection rates, immunologic risks 
and increase in costs 12-15. Pharmacologic agents such as 
tranexamic acid or aminocaproic acid (EACA) could reduce 
perioperative blood loss by interfering with ﬁ brinolysis 16. 
Numerous small trials evaluated the use of antiﬁ brinolytics 
in orthopedic surgery, observing their efﬁ ciency in reducing 
blood loss. Unfortunately, they were underpowered to detect 
efﬁ cacy on more relevant clinical outcomes. Furthermore, 
the remaining concern is that such agents may promote a hy-
percoagulable state within the context of high risk of venous 
thromboembolism, such as in orthopedic surgery 17,18.
This prospective, randomized and controlled study was 
performed to compare the effects of HES 130/0.4 with 
lactated Ringer solution during hip arthroplasty in adult pa-
tients under spinal anesthesia regarding transfusion require-
ments, hemodynamic parameters and clinical postoperative 
complications.
Methods
Study Design and Treatment Strategies
We performed a prospective, randomized and controlled trial 
that enrolled consecutive patients scheduled for elective hip 
arthroplasty at the Instituto de Ortopedia e Traumatologia do 
Hospital das Clínicas da Universidade de São Paulo, Brazil, 
during a 24-month period. Patients were excluded for any 
of the following reasons: age younger than 18 years; obes-
ity (BMI > 40 kg.m-2); chronic kidney disease (creatinine 
clearance lower than 60 mL.min-1.m-2); American Society of 
Anesthesiologists (ASA) physical status classiﬁ cation III or 
higher; chronic anemia (preoperative hemoglobin lower than 
10 g.dL-1); low platelet count (preoperative platelet count 
lower than 150x103.μL-1); coagulopathy (previous history or 
prothrombin time longer than 14.8 seconds); left ventricular 
dysfunction (left ventricular ejection fraction lower than 
40%); myocardial infarction during the last 6 months, unstable 
angina, hepatic dysfunction (total bilirubin level higher than 
1.5 mg.dL-1); and refusal to consent.
The study was approved by the Ethics Committee, 
Hospital das Clínicas, Universidade de São Paulo, and writ-
ten informed consent was obtained from all patients before 
enrollment.  
Patients were randomly assigned to the HES group or lac-
tated Ringer group at a proportion of 1:1. Opaque envelopes 
arranged using a random-number table were prepared by 
the chief statistician and opened sequentially to determine 
the patient´s treatment group. The research coordinator 
enrolled the participants and obtained informed consent. 
Information about the treatment was given to the anesthe-
siologist. Patients and the outcome assessors were blinded 
to group assignments.
Immediately after anesthetic procedure, patients as-
signed to the HES group received 15 mL.kg-1 intravenous of 
HES 6% 130/0.4 and patients assigned to lactated Ringer 
group received 30 mL.kg-1 intravenous of lactated Ringer. 
The trigger for additional ﬂ uid replacement was a systolic 
blood pressure lower than 90 mm Hg and/or a decrease of 
20% from baseline, or heart rate higher than 100 beats per 
minute. Vasopressors were used if there was persistent hypo-
tension despite ﬂ uid replacement. Red blood cell transfusion 
was administered in patients with hemodynamic instability 
(mean arterial pressure lower than 65 mm Hg despite of 
adequate ﬂ uid replenishment) associated with hemoglobin 
lower than 8 g.dL-1.
Anesthesia protocol
Patients were premedicated with 5 mg of intravenous mi-
dazolam in the pre-induction anesthetic room. All patients 
were monitored with non-invasive blood pressure, continuous 
electrocardiography and pulse oximetry. A peripheral cath-
eter 16G under local anesthesia was inserted in the cubital 
vein. Arterial and central venous catheters were placed as 
required. Lumbar spinal anesthesia, preferably into L3/L4 
space with a 27G needle, was performed. A mixture of iso-
baric bupivacaine 20 mg plus morphine 100 μg was used in all 
patients. Sedation with intravenous propofol 0.1μg.kg-1 was 
administered in all patients during the surgical procedure. 
Hypothermia was prevented during the surgery and recov-
ery period with the use of a heating blanket and warmed 
intravenous ﬂ uids. After surgical procedure, all patients 
were transferred to post-anesthetic unit care until complete 
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recovery from anesthesia.  Patients were discharged from 
post-anesthetic unit to regular wards when they met Aldrete-
Kroulic discharge criteria. 
Baseline Assessment and Data Collection
At the time of randomization, demographic and clinical data 
were obtained for each patient. Preoperative laboratory 
values collected up to 24 hours before surgery were recorded 
and included: hemoglobin, hematocrit, prothrombin time, 
active partial thromboplastin time, creatinine level, bilirubin 
level, and platelet count. During surgery, arterial pressure, 
heart rate and pulse oxymetry were recorded immediately 
before and after the regional anesthesia, every 15 minutes 
until the end of the surgery, as well as in the recovery room. 
Blood samples for measurement of hemoglobin levels, arte-
rial blood gas analysis and assessment of coagulation and 
platelet aggregation were collected just before the surgery, 
2 hours after the incision, at the end of the surgery and after 
24 hours of the surgical procedure. Platelet aggregation was 
assessed by light transmission aggregometry using a PAP-4 
aggregometer after ADP infusion 19-20.
Blood losses from the surgical ﬁ eld were calculated by 
computing the amount of blood in surgical aspirators, and 
by weighing surgical sponges during the procedure. In the 
remaining 24 hours of the postoperative period, blood losses 
were considered by obtaining the volume from tube drainage. 
All administered intravenous ﬂ uids and red blood cells were 
recorded from the beginning of the surgery until the ﬁ rst 24 
hours after the surgical procedure. 
During patients’ hospital stay, data were collected regard-
ing the use of RBC transfusion and clinical complications. 
Clinical outcomes were evaluated in a blinded fashion.
Hematological complications were deﬁ ned as impairment 
of platelet aggregation and increase in blood losses during 
perioperative and within the ﬁ rst 24 hours of postoperative 
period. Respiratory complications were deﬁ ned as the need 
for mechanical ventilation and development of pneumonia 
or acute respiratory distress syndrome (ARDS) deﬁ ned by 
standard criteria 21. Cardiac complications included car-
diogenic shock, tachyarrhythmia or perioperative cardiac 
ischemia 22.
Renal function was evaluated daily using RIFLE (Renal 
risk, Injury, Failure, Loss of kidney function, End-stage kidney 
disease) classiﬁ cation 23. The need for renal replacement 
therapy was recorded. 
Infectious complications included: septic shock - de-
ﬁ ned by standard criteria); pneumonia - deﬁ ned by a new 
lung inﬁ ltrate on chest radiography and the presence of 
at least two of the following criteria: temperature of 
38ºC or higher, leukocytosis greater than 12,000 cells.
μL-1 or leucopenia lower than 3,000 cells.μL-1, or purulent 
endotracheal secretions with a Gram stain showing more 
than 25 neutrophils and fewer than 10 epithelial cells per 
ﬁ eld; wound infection - deﬁ ned as a superﬁ cial or deep 
infection of the wound with positive ﬁ ndings on cultures 
obtained from the wound 24.
Outcome Measures
The primary outcome was red blood transfusion requirement 
from operation time until 30 days after surgical procedure. 
Secondary outcomes included a comparison of hemodynamic 
variables and tissue perfusion parameters between groups 
during the surgical procedure, and postoperative incidence 
of all complications, including infectious, hematological, 
cardiovascular, respiratory and renal complications, and 
hospital length of stay. 
Statistical Analysis 
The sample size was calculated assuming a 40% incidence 
in transfusion requirement in crystalloid group. Considering 
an alpha error of 0.05 and a statistical power of 0.80, we 
determined that a minimum of 23 patients in each group was 
necessary to conduct the present study. 
Results are expressed as means with 95% conﬁ dence 
intervals (CIs) or medians with interquartile ranges (IQR). 
Continuous variables were compared using a t test or Mann-
Whitney U test and categorical variables using Pearson 
chi-square or Fisher’s exact test. The differences between 
and within the groups were analyzed with one-way analysis 
of variance on ranks. Tests were 2-tailed, and values of 
p < 0.05 were considered statistically signiﬁ cant. Statistical 
analyses were performed using SPSS version 18.0 (SPSS Inc, 
Chicago, Illinois).
Results
A total of 48 patients were enrolled in the study: 24 as-
signed to the HES group 130/0.4 and 24 in the lactated 
Ringer group.  Baseline characteristics were well matched 
between study groups (Table 1). Anesthetic requirements 
and duration of surgery were also similar in the groups. 
There was no difference regarding intraoperative body 
temperature and hemodynamic parameters - heart rate, 
systolic and diastolic pressures between groups (Table 2). 
No difference was found with regards to urinary output, 
need for norepinephrine, inotropic support and additional 
ﬂ uid administration.
Coagulation parameters, hemoglobin and hematocrit val-
ues at different times were similar in both groups (Table 3). 
The analysis of arterial blood gas did not reveal any differ-
ence between groups in values of arterial pH, partial pressure 
of oxygen, partial pressure of carbon dioxide, base excess 
and bicarbonate (Table 4). Biochemical analysis was not dif-
ferent between groups (Table 5). 
Clinical Outcomes 
Perioperative Blood Transfusion 
In the Ringer group, 11 patients (46%) needed RBC transfu-
sion during hospital stay compared to four patients (17%) in 
the HES group (p = 0.029) (Figure 1).
Platelet Aggregation
Platelet aggregation tests were signiﬁ cantly impaired in 
the HES group when compared to lactated Ringer group 
(Figure 2). D = the difference between groups was demon-
strated immediately after HES infusion (p = 0.042), after 
two hours (p = 0.029) and at the end of surgical procedure 
(p = 0.029).
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Table 1  Baseline Characteristics of Study Patients.
Variable HES 130 / 0.4
(N = 24)
Lactated Ringer
(N = 24)
p
Age (years) - mean (95%CI) 54 (47 to 61) 53 (47 to 59) 0.889
Male sex - N (%) 14 (58.3%) 9 (37.5%) 0.149
Weight (kg) - mean (95%CI) 74 (71 to 77) 71 (66 to 75) 0.248
Duration of surgery (mim) - median (IQR) 158 (120 to 190) 155 (135 to 180) 0.860
Duration of anesthesia (min) - median (IQR) 208 (180 to 240) 225 (169 to 240) 0.615
CI: Conﬁ dence Interval, IQR: Interquartile range.
Table 2  Hemodynamics and Clinical Variables of Patients Undergoing Hip Arthroplasty.
Mean (95%CI)
HES 130 / 0.4
(N = 24)
Lactated Ringer
(N = 24)
p
Heart Rate (bpm)
   Baseline 77 (74 to 81) 78 (73 to 83) 0.058
   2h after incision 80 (76 to 85) 72 (67 to 77) -
   End of surgery 83 (79 to 87) 75 (70 to 80) -
Systolic blood pressure (mm 
Hg)
   Baseline 131 (124 to 138) 131 (126 to 137) 0.508
   2h after incision* 109 (102 to 115) 103 (98 to 108) -
   End of surgery* 112 (107 to 118) 111 (107 to 115) -
Dyastolic blood pressure (mm 
Hg)
   Baseline 79 (75 to 83) 82 (77 to 87) 0.508
   2h after incision* 63 (59 to 67) 57 (53 to 62) -
   End of surgery* 66 (63 to 69) 66 (61 to 71) -
Body temperature (ºC)
   Baseline 36.3 (36.2 to 36.4) 36.3 (36.2 to 36.4) 0.508
   2h after incision* 36 (36 to 36.1) 35.9 (35.8 to 36.1) -
   End of surgery* 36.2 (36.1 to 36.4) 36.1 (35.9 to 36.2) -
CI: Conﬁ dence Interval; * signiﬁ cant difference with baseline.
Perioperative Blood Loss
The total amount of blood loss was signiﬁ cantly higher in HES 
group (mean 1.296 mL ± 673.24 in HES group versus 890.00 ± 
566.54 mL in lactated Ringer group; p < 0.0460) (Figure 3).
Secondary Outcomes
There were no signiﬁ cant differences between groups in 
hospital mortality or in length of stay either in the post-
anesthetic care unit or in regular wards (Table 6). There 
were no differences in the occurrence of cardiac compli-
cations, respiratory complications or renal complications. 
Patients treated with lactated Ringer had a higher number 
of infectious complications (4/24, 17%) than the HES group 
(0) (p = 0.03). Three patients presented wound infection and 
one patient had prosthesis infection. One postoperative death 
occurred in the HES group secondary to myocardial infarction 
leading to fatal cardiogenic shock. 
Discussion
In patients undergoing hip arthroplasty, ﬂ uid replacement 
with hydroxyethyl starch 130/0.4 resulted in higher rates 
of bleeding when compared to those that received lactated 
Ringer. Conversely, starch treated patients required less 
transfusion, and presented a lower rate of infection. The 
higher rates of bleeding attributed to the HES group did not 
compromise the clinical outcomes of these patients. 
Elective major orthopedic surgery was chosen because it 
offers a common and standard surgical setting that allowed 
the study design to be largely based on clinical routine. The 
crystalloid-colloid volume ratio of 2:1 was established based 
on previous studies that compared the effectiveness of col-
loids against crystalloids 18,25,26.
In our study, the higher impact of colloids on platelet 
aggregation tests did not seem to result in worse clinical 
outcomes, as the HES group received less transfusion. The 
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hypothesis for this ﬁ nding is that colloids accounted for 
improved hemodynamic stability; therefore, few patients 
in this group needed transfusion.
Considering the deleterious effects produced by alloge-
neic transfusion in different clinical scenarios 27 and consist-
ent data showing a relatively low impact of new generations 
of starch on coagulation 28, HES administration would be an 
attractive alternative to traditional ﬂ uid replacement in 
major orthopedic surgeries under spinal anesthesia. 
Traditional protocols involve ﬂ uid expansion with crystal-
loid and liberal protocol of allogeneic transfusion. In fact, 
evidence from previous studies showing beneﬁ ts of allogeneic 
blood transfusion is deeply hindered by a signiﬁ cant number 
of underpowered studies with a small-sized population. 
In addition, the TRICC trial (Transfusion Requirements in 
Critical Care) - the only large RCT that compared a restric-
tive versus a liberal transfusion strategy - was sufﬁ ciently 
powered to favor a restrictive transfusional trigger in clini-
cal ICU patients 11. In a large orthopedic trial undertaken 
in 1999, a total of 2,640 hip and 1,305 knee arthroplasty 
patients were evaluated 29. A total of 2,762 (69%) received 
transfusion, of which only 35% autologous and 25% allogeneic. 
The most important ﬁ nding of this study was that the rate of 
wound infections was signiﬁ cantly higher (4.2% vs. 1%) when 
comparing patients exposed to allogeneic and autologous 
transfusion, respectively 29.
 Nevertheless, common techniques that may reduce allo-
geneic blood transfusion during major surgeries - such as the 
acceptance of lower levels of hemoglobin before transfusion 
decision, routine use of acute normovolemic hemodilution 
(ANH), cell salvage and pharmacological haemorrhage control 
- are not systematically used in most countries 30,37. Although 
being extremely feasible, ANH is not largely employed. We 
have extensively investigated experimentally the effects of 
ANH on the heart 31, lungs 32 and different organs 33. In these 
experimental studies, results favored colloid over crystalloid 
ﬂ uid replacement that concerns cellular and organ architec-
ture preservation. In our study, however, patients submitted 
to hypervolemic hemodilution with starch 130/0.4 presented 
more bleeding than those who received moderate quantities 
of lactated Ringer. This could be the result of hemodilution 
and/or direct action of starch on the coagulation system. 
Table 3  Hematological Analysis of Patients Undergoing Hip Arthroplasty.
Mean (95%CI)
HES 130 / 0.4
(N=24)
Lactated Ringer
(N=24)
p
Thrombin time (sec)
   Baseline 1.01 (0.98 to 1.04) 1.01 (0.98 to 1.03) 0.346
   2h after incision* 1.03 (1 to 1.06) 1.04 (1.02 to 1.06) -
   End of surgery* 1.03 (1 to 1.07) 1.06 (1.04 to 1.09) -
   24h after surgery* 1.02 (0.99 to 1.05) 1.04 (1 to 1.08) -
Prothrombin time (sec)*
   Baseline 1.03 (0.98 to 1.08) 1.43 (0.62 to 2.24) 0.597
   2h after incision 1.08 (1.03 to 1.12) 1.05 (1.02 to 1.08) -
   End of surgery 1.18 (1.08 to 1.27) 1.12 (1.07 to 1.17) -
   24h after surgery 1.21 (1.08 to 1.34) 1.12 (1.07 to 1.17) -
Partial thromboplastin time (sec)
   Baseline 1.04 (1 to 1.09) 1.4 (0.59 to 2.21) 0.612
   2h after incision 1.09 (1.04 to 1.14) 1.02 (0.98 to 1.06) -
   End of surgery 1.1 (1.04 to 1.16) 1.03 (0.99 to 1.07) -
   24h after surgery 1.08 (1.02 to 1.15) 1.07 (1 to 1.15) -
Hemoglobin (g/dL)
   Baseline 13.8 (13.1 to 14.5) 13.6 (13 to 14.3) 0.629
   2h after incision* 10.4 (9.7 to 11.2) 10.9 (10.1 to 11.7) -
   End of surgery* 9.9 (9.4 to 10.3) 10.1 (9.1 to 11.2) -
Hematocrit (%)
   Baseline 42 (40 to 44) 41 (39 to 43) 0.772
   2h after incision* 31 (29 to 34) 32 (30 to 35) -
   End of surgery* 30 (28 to 31) 30 (27 to 33) -
CI: Conﬁ dence Interval; * signiﬁ cant difference with baseline.
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Table 4  Gas Analysis of Patients Undergoing Hip Arthroplasty.
Mean (95%CI)
HES 130 / 0.4
(N = 24)
Lactated Ringer
(N = 24)
p
pH
   Baseline 7.37 (7.36 to 7.39) 7.38 (7.36 to 7.39) 0.240
   2h after incision* 7.37 (7.34 to 7.39) 7.32 (7.3 to 7.35) -
   End of surgery* 7.33 (7.3 to 7.35) 7.33 (7.3 to 7.35) -
   24h after surgery 7.37 (7.35 to 7.39) 7.36 (7.34 to 7.37) -
Arterial PO2 (mm Hg)
   Baseline 100 (84 to 117) 104 (90 to 119) 0.206
   2h after incision* 143 (115 to 171) 155 (136 to 174) -
   End of surgery* 111 (97 to 125) 131 (112 to 151) -
   24h after surgery 95 (93 to 97) 99 (93 to 105) -
Arterial PCO2 (mm Hg)
   Baseline 41 (39 to 43) 43 (38 to 47) 0.742
   2h after incision 43 (40 to 45) 42 (39 to 45) -
   End of surgery 43 (41 to 46) 43 (41 to 46) -
   24h after surgery 41 (39 to 42) 41 (39 to 43) -
Base excess (mmol.L-1)
   Baseline -0.72 (-1.37 to -0.06) -0.33 (-1.31 to 0.65) 0.894
   2h after incision* -1.66 (-2.61 to -0.71) -1.38 (-2.47 to -0.3) -
   End of surgery* -2.59 (-3.71 to -1.47) -2.61 (-3.66 to -1.56) -
   24h after surgery -0.62 (-1.36 to 0.12) -1 (-1.68 to -0.31) -
Sodium bicarbonate (mEq.L-1)
   Baseline 24 (24 to 25) 24 (23 to 25) 0.577
   2h after incision* 23 (22 to 24) 23 (22 to 24) -
   End of surgery* 23 (21 to 24) 22 (21 to 23) -
   24h after surgery 24 (23 to 25) 24 (23 to 24) -
CI: Conﬁ dence Interval; * signiﬁ cant difference with baseline.
Considering the effects of hemodilution, Ruttman and col-
leagues 34 aimed to investigate whether hemodilution altered 
coagulation in patients scheduled to peripheral vascular sur-
gery under regional anesthesia. Although much less volume 
was used in both groups compared to our study, the colloid 
group showed no coagulation disorder. In contrast, those 
who received more crystalloids presented more changes in 
the coagulation proﬁ le measured by thromboelastography. 
They concluded that this was caused by plasmatic dilution 
determined by rapid crystalloid infusion. 
In our study, patients treated with starch showed more 
bleeding. This was possibly due to acute hemodilution, since 
30 mL.kg-1 was employed, in an attempt to maintain the 
patient hemodinamically stable without the need for further 
transfusion. The direct effects of starch on hemostasis and 
coagulation should also be considered. The platelet aggrega-
tion test used in our investigation was signiﬁ cantly affected 
and this ﬁ nding stresses the more pronounced effects of 
starches on platelet function when compared to the effects 
on other components of the hemostatic system, as shown by 
several studies. Kozek-Langenecker et al. 35 described the 
molecular mechanism of starches on the coagulation system. 
According to this study, the low-molar substitution is the 
main determinant of increased metabolic degradation, which 
ascertains undesirable effects, particularly on hemostasis. 
Slowly degradable HES, characterized by high- and medium-
molecular weight, determine plasmatic reduction on the 
levels of factor VIII and vWF. At the same time, it decreases 
platelet reactivity under two mechanisms: decrease in the 
availability of the platelet ﬁ brinogen receptor glycoprotein 
IIb–IIIa and interference on platelet-linking properties of 
vWF. On the other hand, fast degradable HES solutions with 
medium- and low-molecular weight showed reduced effects 
on hemostasis. 
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Table 5  Biochemical Findings of Patients Undergoing Hip Arthroplasty.
Mean (95%CI)
HES 130 / 0.4
(N=24)
Lactated Ringer
(N=24)
p
Sodium (mEq.L-1)
   Baseline 141 (139 to 142) 139 (138 to 140) 0.055
   2h after incision 140 (139 to 141) 138 (137 to 139) -
   End of surgery 139 (139 to 140) 139 (138 to 140) -
   24h after surgery 139 (138 to 140) 138 (137 to 140) -
Potassium (mEq.L-1)
   Baseline 4.2 (4 to 4.4) 4.2 (4 to 4.4) 0.746
   2h after incision* 3.9 (3.8 to 4.1) 4 (3.8 to 4.2) -
   End of surgery* 3.9 (3.8 to 4) 3.9 (3.8 to 4) -
   24h after surgery* 3.9 (3.7 to 4) 3.9 (3.8 to 4) -
AST (U/L)
   Baseline 20.8 (17.3 to 24.4) 19.1 (16.9 to 21.3) 0.162
   2h after incision 21.6 (18.7 to 24.5) 18.7 (16.7 to 20.7) -
   End of surgery 21 (17.8 to 24.1) 18.9 (17.1 to 20.6) -
   24h after surgery 22.3 (18.6 to 26) 18.5 (16.1 to 20.9) -
ALT (U/L)
   Baseline 19.3 (16.7 to 21.9) 17.1 (14.2 to 20.1) 0.091
   2h after incision 19 (16.8 to 21.2) 17 (15 to 18.9) -
   End of surgery 19.3 (17.1 to 21.4) 16.7 (14.9 to 18.4) -
   24h after surgery 20.5 (17.7 to 23.2) 16.8 (14.7 to 18.8) -
Serum glucose (mg.dL-1)
   Baseline 93 (87 to 98) 96 (91 to 100) 0.617
   2h after incision* 102 (96 to 108) 100 (96 to 104) -
   End of surgery* 104 (97 to 111) 100 (96 to 104) -
   24h after surgery* 108 (99 to 118) 105 (96 to 113) -
Serum creatinine (mg.dL-1)
   Baseline 0.86 (0.77 to 0.95) 0.82 (0.71 to 0.92) 0.336
   24h after surgery* 0.97 (0.88 to 1.05) 0.87 (0.75 to 0.99) -
CI: Conﬁ dence Interval; * signiﬁ cant difference with baseline.
In this context, Gandhi et al. 10 compared the safety of 
two starches (HES 130/0.4 vs. HES 670/0.75 in saline) during 
major orthopedic surgery 10. The primary safety endpoints 
were calculated: total erythrocyte loss, the nadir factor VIII 
activity, and the nadir von Willebrand factor concentration 
within 2 hours of surgery completion. The total volume of 
colloid solution required for intraoperative volume replace-
ment did not differ between HES 130/0.4 and hetastarch. The 
nadir factor VIII activity within 2 hours of the end of surgery 
decreased in both groups, but was lower for hetastarch than 
for HES 130/0.4 (p = .0499). For those who received more 
than 1,000 mL of colloid, von Willebrand factor levels also 
decreased in both groups within 2 hours of the end of surgery, 
but the concentration was lower for hetastarch than for HES 
130/0.4. They concluded that HES 130/0.4 and hetastarch 
were equally effective as plasma volume expanders, with HES 
130/0.4 showing a lesser effect on coagulation 10. Our study 
showed a similar ﬁ nding of the low impact of HES 130/0.4 on 
coagulation tests, except for platelet aggregation. 
The impact of blood transfusion on infection rates was 
determined by several studies 11,29 that correlated immuno-
logical interplay between blood transfusion and infection. 
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In our study, the Ringer group required more transfusion and 
had a higher rate of infection. Four patients in this group 
had postoperative infection, and one of them was submit-
ted to three surgical procedures combined with antibiotic 
therapy.  
Fluid replacement with HES 130/0.4 resulted in reduced 
transfusion rates and in lower incidence of infection, com-
pared to crystalloid solution, an outcome that suggests that 
colloid-induced hypervolemic hemodilution would be an at-
tractive strategy to be applied in orthopedic surgery.
Table 6  Clinical Outcomes in Patients Undergoing Hip Arthroplasty.
Variable HES 130 / 0.4
(N = 24)
Lactated Ringer
(N = 24)
p
Length of hospital stay (days) – median (IQR) 5  (3 to 7) 5 (4 to 6) 0.323
Cardiovascular complication 1/24 (4%) 0/24(0%) 1.000
Infection 0/24 (0%) 4/24 (17%) 0.037
Renal complication 1/24(4%) 0/24(0%) 1.000
Respiratory complication 1/24(4%) 0/24(0%) 1.000
Death 1/24 (4%) 0/24 (0%) 1.000
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Figure 1  Relative Frequencies of Red Blood Cell Transfusion in 
Perioperative Period in Patients Undergoing Hip Arthroplasty.
Figure 3  Platelet Aggregation After ADP Infusion in Patients 
Undergoing Hip Arthroplasty.
Figure 2  Blood Loss in Perioperative Period in Patients 
Undergoing Hip Arthroplasty.
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